Categories AlphaGraphs, Earnings, Health Care
AbbVie (ABBV) Q2 2020 results beat estimates; updates FY20 outlook
AbbVie (NYSE: ABBV), which completed the acquisition of Allergan on May 8, 2020, reported second quarter 2020 earnings results today. The company’s adjusted earnings and revenue in Q2 bettered the market’s estimates. which included a partial quarter of Allergan and COVID-19 pandemic impact.
ABBV stock was trading up about 2% in the before market hours.
On an adjusted basis, earnings increased to $2.34 per share from $2.26 per share in the year-ago quarter. On a GAAP basis, AbbVie posted a loss of $0.46 per share compared to a profit of $0.49 per share in the second quarter of 2019.
Revenues of $10.425 billion, increased 26.3% on a reported basis, and decreased 5.3% on a comparable operational basis, due to the COVID-19 pandemic.
Also read: Strong performance of oncology products bode well for AbbVie (ABBV) going forward
AbbVie provided combined company earnings outlook for fiscal 2020, which includes the results of Allergan from May 8, 2020 through December 31, 2020. The company now expects GAAP EPS to be in the range of $4.12 to $4.22. On a non-GAAP basis, profit is now expected to be in the range of $10.35 to $10.45 per share.
Most Popular
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported worldwide net revenues of $13.3 billion for the
Colgate-Palmolive (CL) Q1 2025 Earnings: Key financials and quarterly highlights
Colgate-Palmolive Company (NYSE: CL) reported its first quarter 2025 earnings results today. Net sales decreased 3.1% year-over-year to $4.9 billion. Organic sales growth was 1.4%. Net income attributable to Colgate-Palmolive Company rose
Meta Platforms (META) set to report Q1 earnings. Here’s what to expect
After integrating artificial intelligence into its products, Meta Platforms, Inc. (NASDAQ: META) is investing heavily in the metaverse project. Yet, the tech giant has maintained healthy cash flows and consistently
Comments